Emmaus Life Sciences Company Description
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug.
The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011.
Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Willis Lee |
Contact Details
Address: 21250 Hawthorne Boulevard Torrance, California California United States | |
| Phone | 310 214 0065 |
Stock Details
| Ticker Symbol | EMMA |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US29137T1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Willis C. Lee M.S. | Chief Executive Officer and Chairman of the Board |
| Hiroko Huynh CPA | Chief Accounting Officer |
| Dr. Charles W. Stark Pharm.D. | Chief Science Officer and Executive Vice President of Clinical Development and Medical Affairs |
| Dale E. Short J.D. | Legal Consultant and Corporate Secretary |
| Kurt H. Kruger M.B.A., M.S. | Consultant |